State of the State January 25, 2019 Presenting to APIC Grand Canyon | Phoenix AZ Arizona Department of Health Services Update on the Syphilis Outbreak Rebecca Scranton, MPH Program Manager ADHS STD Control A Brief History of Syphilis in Arizona How does syphilis compare?

STDs in Arizona Syphilis represents 4% of STDs

Only 1:4 syphilis cases are women

2007 2018 Outbreak declared!

Directors Blog, September 25, 2018 Why syphilis?

STDs in Arizona Syphilis in Arizona

Status TBD Case

2007 2018 2007 2018 Outbreaks can last for years

Syphilis Timeline

6.5 mo

Exposure >1 mo 1.5 mo 1.5 mo

• 2 Infectious periods, last > 1 month • Up to 6.5 months between exposure and start of 2nd infectious period • Some cases can relapse into a 3rd infectious period at any time • Pregnant women can pass the disease to their developing baby at any time What about the babies?

Congenital syphilis started to increase in 2017

Status TBD Survived Died 2014 2015 2016 2017 2018 Statewide increase of CS

Congenital Syphilis in Arizona 1 2 3 4 5+ Number of congenital cases

2014 2015 2016 2017 2018 What are we doing about it? Statewide actionAction Planplan

Awareness Partnerships Screening Why screening?

Syphilis Timeline

Exposure Primary Secondary CDC Screening Recommendations

Pregnant At first prenatal visit, retest women at third trimester and at delivery if at high risk MSM Annually HIV+ Annually Effective Jan 1, 2018; A healthcare provider for a pregnant syphilis case shall order serologic testing for syphilis at 28 to 32 weeks gestation and at delivery

A.R.S. § R9-6-381 A-2 Missed opportunities

77% of moms saw a provider > 30 days 77% prior to delivery

1/3 of CS cases could have been prevented 36% through third trimester testing Risk factors included meth, heroin, cocaine, and/or opiates. IV drug 12% 46% use was also reported. ADHS CDC Screening Recommendations

Pregnant At first prenatal visit, retest women at third trimester and at delivery if at high risk - Create electronic reminder systems MSM Annually HIV+ Annually Drug Opt out screening for men & users women that use drugs AHCCCS Covers 3 Screenings! Summary Action Plan

Syphilis is [still] Screening is increasing important

2007 2018 Coming Soon!

Annual HIV/STD/TB Clinical Update

2nd Annual Tribal STD/HIV Conference

[email protected] azdhs.gov/std Thanks!

Rebecca Scranton STD Control Program Manager [email protected] Rabies Post-Exposure Prophylaxis

APIC State of the State

Hayley D. Yaglom, MS, MPH 1/25/2019 Senior Epidemiologist Vector-borne & Zoonotic Diseases Program What is Rabies?

RNA virus in the family Rhabdoviridae.

Rabies virus infects the central nervous system.

Disease is progressive and rapidly fatal. How is Rabies Spread?

The bite of an infected animal.

Mucous membrane, scratch, abrasion, or open wound contact with saliva or other potentially infectious material.

Inhalation of aerosolized rabies virus is also a possibility.

Petting a rabid animal or contact with the blood, urine or feces does not constitute an exposure. Rabies in Arizona

Arizona is home to three rabies reservoirs: bats, gray foxes, and skunks. Rabies in Arizona

In 2018, we had 159 positive rabid animals.

51 domestic animals exposed to rabid animals.

29 humans exposed to rabid animals. What is Rabies Post-Exposure Prophylaxis?

Rabies post-exposure prophylaxis (PEP) involves wound cleansing, administration of human rabies immune globulin (HRIG) and a series of vaccinations. Human Rabies Immune Globulin Recommended dose is 20 IU/kg body weight (all age groups).

Infiltrate one time into wound and surrounding area.

Remaining volume should be injected intramuscularly (IM). Human Rabies Immune Globulin

If there is no wound, the entire dose of HRIG should be administered IM. Human Rabies Immune Globulin

Provides immediate antibodies until the body can respond to the vaccine.

Can be administered up to 7 days after the first dose of vaccine.

Not recommended beyond day 7 since an antibody response to the vaccine is presumed to have occurred.

Rabies Post-Exposure Prophylaxis Vaccines

RabAvert (PCECV) and Imovax (HDCV) are considered interchangeable in terms of indications for use, immunogenicity, efficacy and safety.

Other types of tissue culture and avian culture vaccines are available in other countries and are considered interchangeable. rPEP Vaccine Administration Reminders

First vaccine dose should never be administered in the same syringe or in the same anatomical site as HRIG.

Subsequent doses of vaccine in the series can be administered in the location where HRIG dose was given.

Pregnancy is not a contraindication to PEP. Rabies Post-Exposure Prophylaxis Schedule

Immunocompetent Individual HRIG and first vaccination are given on the first day of treatment (day 0), and three additional vaccinations are given on days 3, 7, and 14.

Immunocompromised Individual Receive a 5th vaccination on day 28 and tested for seroconversion 7-14 days following completion of PEP.

Previously Vaccinated Individual (either pre or post-exposure) Receive only two rabies vaccine boosters on days 0 and 3, and NO HRIG. Rabies PEP: Immunocompetent People (including pregnant women) Rabies PEP: Immunocompromised and Previously Vaccinated People Deviations from Recommended Schedule After day 3 of the regimen, deviations of a few days are acceptable.

For most minor delays or interruptions, the vaccination schedule can be shifted and resumed as though the patient were on schedule. Special Considerations

[email protected]

602-364-3676 Resources

CDC Rabies Webpage www.cdc.gov/rabies https://www.cdc.gov/rabies/medical_care/index.html https://www.cdc.gov/rabies/medical_care/vaccine.html https://www.cdc.gov/rabies/resources/acip_recommendations.html https://www.cdc.gov/rabies/resources/availability.html

Use of a Reduced (4-Dose) Vaccine Schedule for Post-exposure Prophylaxis to Prevent Human Rabies: Recommendations of the Advisory Committee on Immunization Practices https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5902a1.htm

Human Rabies Prevention —United States, 2008 Recommendations of the Advisory Committee on Immunization Practices https://www.cdc.gov/mmwr/PDF/rr/rr5703.pdf

http://www.who.int/vaccine_safety/initiative/tools/Rabies_Vaccine_rates_information_sheet.pdf

https://azdhs.gov/documents/preparedness/epidemiology-disease-control/rabies/rabies-post-exposure-management.pdf Questions

[email protected] | 602-542-2521 | [email protected] | 602-364-3676 Tuberculosis + HIV Testing

TB Control Program TB Surveillance Epidemiologist Evan Timme

APIC – State of the State Friday, January 25th, 2019 Disclosures:

• No known conflicts of interest TB: By the Numbers

Today vs 1975 TB: By the Numbers

Today vs 1975

<200 >400 TB: By the Numbers

Today vs 1975

<200 >400

<3/100,000 19/100,000 TB: By the Numbers

2 0 1 8 ?

2012 2017 TB: By the Numbers

2012 2017 TB & HIV

Surveillance Review TB & HIV

Surveillance Review

• 1993  2016 TB  HIV TB & HIV

ID Week 2018: Poster #2263 p < 0.0001 TB & HIV

Site of Dz

ID Week 2018: Poster #2263 p < 0.0001 TB & HIV

ID Week 2018: Poster #2263 TB & HIV

ID Week 2018: Poster #2263 TB & HIV

Outcome

ID Week 2018: Poster #2263 p < 0.0001 TB & HIV

HIV Dx Years Date

ID Week 2018: Poster #2263 TB & HIV

More than 93% of persons Dx with TB & HIV were Dx with HIV BEFORE Tuberculosis Dx.

HIV Dx Years Date

ID Week 2018: Poster #2263 TB & HIV

Without treatment, on average 1 in 10 people with latent TB will get sick with TB disease in the future.

The risk is higher for persons living with HIV.

HIV Dx Years Date

ID Week 2018: Poster #2263 https://www.cdc.gov/tb/topic/treatment/decideltbi.htm Know your TB Program TB: In the Works

2019: New Healthcare Personnel TB Screening Guidelines Thanks for the opportunity to share some work.

ADHS TB Control [email protected]

APIC-SotS: Friday, January 25th, 2019 Acute Flaccid Myelitis

Susan Robinson, MPH Vaccine Preventable Disease Epidemiologist

What is AFM? Acute Flaccid Myelitis

Acute onset of Limb weakness Inflammation of the symptoms *Can also include facial droop* spinal cord Acute Flaccid Myelitis

Acute onset of Limb weakness Inflammation of the symptoms *Can also include facial droop* spinal cord

One limb or all four limbs may be affected How is it diagnosed? MRI imaging Pleocytosis

o White blood cell count > 5 cells/mm3

JAMA. 2015;314(24):2663-2671. doi:10.1001/jama.2015.17275 How is it treated? No current targeted therapies or interventions currently available No current targeted therapies or interventions currently available o Supportive care o Physical therapy and rehabilitation early Are there lab tests? Short answer: Short answer: no

Specific pathogens to consider: Specific pathogens to consider:

oEnteroviruses (polio and non-polio) Specific pathogens to consider:

oEnteroviruses (polio and non-polio)

oWNV Specific pathogens to consider:

oEnteroviruses (polio and non-polio)

oWNV

oAdenoviruses Current AFM surveillance?

4

2

1 1 1 1 1 1 1 4

2

1 1 1 1 1 1 1

First year of surveillance in the US 4

2

1 1 1 1 1 1 1

A cluster was seen at PCH 14 cases reported over 5 years of surveillance 14 cases reported over 5 years of surveillance

Mean age: 9.5 years old Range: 17 months to 23 years 14 cases reported over 5 years of surveillance

Mean age: 9.5 years old Range: 17 months to 23 years 14 cases reported over 5 years of surveillance

Mean age: 9.5 years old Range: 17 months to 23 years

Over 50% of AZ cases had 4 limbs involved. Considerations for EVD68? Bradford Hill criteria: Bradford Hill criteria:

Strength of association Strength of association Bradford Hill criteria:

Strength of association

Consistency Consistency Bradford Hill criteria:

Strength of association

Consistency

Specificity Specificity

Not supported Bradford Hill criteria:

Strength of association

Consistency

Specificity

Temporality Temporality

o Generally febrile respiratory or GI prodrome precedes onset of neurological symptoms

o Respiratory specimens collected in that prodrome timeframe are positive prior to onset of neurological symptoms Bradford Hill criteria:

Strength of association

Consistency

Specificity

Temporality

Biological gradient Biological gradient

Not supported Bradford Hill criteria:

Strength of association

Plausibility

Consistency

Specificity

Temporality

Biological gradient Plausibility Bradford Hill criteria:

Strength of association

Plausibility

Consistency

Coherence

Specificity

Temporality

Biological gradient Coherence

o Viremia detected early in the course of enterovirus D68 infection and neuron-specific receptors for EV-D68 provide potential mechanism for neuroinvasion Bradford Hill criteria:

Strength of association

Plausibility

Consistency

Coherence

Specificity

Experiment

Temporality

Biological gradient Experiment

o Recent EV-D68 mice studies o EV-D68 causes loss of motor neurons in anterior horn of spinal cord in mice

o EV-D68 isolated from the spinal cord of paralyzed mice transmits paralytic disease to naïve mice

o EV-D68 antibodies protect against paralytic disease in mice Bradford Hill criteria:

Strength of association

Plausibility

Consistency

Coherence

Specificity

Experiment

Temporality

Analogy

Biological gradient Analogy

o Recent EV-D68 mice studies o EV-D68 causes loss of motor neurons in anterior horn of spinal cord in mice

o EV-D68 isolated from the spinal cord of paralyzed mice transmits paralytic disease to naïve mice

o EV-D68 antibodies protect against paralytic disease in mice Bradford Hill criteria:

Strength of association

Plausibility

Consistency 7 out of 9 criteriaCoherence met! Specificity

Experiment

Temporality

Analogy

Biological gradient THANK YOU

Susan Robinson, MPH | Vaccine Preventable Disease Epidemiologist [email protected] | 480-435-3929

azhealth.gov @azdhs facebook.com/azdhs Would you like some E.coli with your salad?

Kaitlyn Snyder Foodborne Disease Epidemiologist Arizona Department of Health Services March 2018

October 2018

MEDSIS Update January 25th, 2019

Presenting To APIC State of the State | Maricopa County Department of Teresa Jue | EDC Systems Manager What happened in 2018?

Four MEDSIS Production releases

Secure Messaging Resources Other enhancements & bug fixes Cloud Migration Health Services Portal https://connect.azdhs.gov What’s next?

Cloud Optimization

2019 Prioritization How do I submit feedback?

MEDSIS Infection Preventionist Quarterly Workgroup Meetings

MEDSIS Help Desk [email protected] THANK YOU

Teresa Jue | EDC Systems Manager [email protected] | 602-364-0151

[email protected]

azhealth.gov/medsis @azdhs facebook.com/azdhs APIC January 25, 2019 Creating Arizona Statewide Antimicrobial Stewardship Initiatives

Leadership Commitment

Accountability

Drug Expertise

Action AS Initial Project Description

(Arizona LTCF’s)

(Pharmacies) (Microbiology Labs) AS Future Directions

• Expand into additional Tracking facilities

• Provide targeted AS Reporting interventions

• Develop LTCF AS Toolkits Education Questions?

Juan E. Villanueva, PharmD, BCPS Assistant Professor Email: [email protected] Office: 520.626.5764 ADHS HAI Quarterly TAPS Report Trends Facility Outreach

Identify facilities that Provide these facilities consistently aren’t meeting with CDC TAPS 2020 HHS Target Goals Assessment Tools Facility consistently above the 2020 target SIR goals

ADHS is targeting high infection rates from recent quarters 2018 Quarter 1 NHSN Data Observed Predicted Quarterly CAD* Infections SIR 3 4.614 0.7 1 Number of infections that need to be 2018 Quarter 2 NHSN Data prevented to Observed Predicted Quarterly reach 2020 HHS CAD* Infections Infections SIR target goals 4 3.197 1.2 3 1. Let facilities know about high HAI rates at their hospital 2. Share HAI specific CDC TAPS Assessment Tool 3. Explain how to perform this assessment 4. Encourage facilities to reach out to the state and local health departments TAPS Facility Instructions for Assessment Tool Administration: This Facility Assessment Tool should be administered to a variety of staff and healthcare personnel at different levels of the organization and/or unit (i.e., frontline providers, mid-level staff, and senior leadership). This assessment captures healthcare personnel’s knowledge, attitudes, and perceptions of infection prevention practices. The greater number of assessments collected, the greater the ability to identify gaps and target prevention.

Thank You! Questions?

[email protected] Arizona Influenza Update January 25, 2019

Presenting To APIC Grand Canyon’s State of the State Phoenix, AZ

Xandy Peterson, MPH

Vaccine-Preventable Disease Epidemiologist 2017-2018 Influenza Season In 2017-2018, there were 35,520 laboratory confirmed cases.

5 Season Average 2015–2016 2016–2017 2017–2018 6,000

5,000

4,000

3,000

2,000 Number Number Cases of 1,000

0

Week of Report 2018-2019 Influenza Season In the past week, there were 863 laboratory confirmed cases for a season total of 6,603.

5 Season Average (2013–2017) 2016–2017 2017–2018 2018–2019 6,000

5,000

4,000

3,000

Number of Cases Cases of Number 2,000

1,000

0

Week of Report

For the season, 90% are type A, 8% are type B, and 2% are unknown. 2018-2019 Season 2017-2018 Season

0 to 4 years 15% 24%

5 to 18 years 19% 29%

19 to 49 years 24% 25%

50 to 64 years 12% 14%

65 years or older 11% 28%

0% 5% 10% 15% 20% 25% 30% 35% Influenza-like Illness (ILI) Surveillance

Fever and Cough or Sore Throat Influenza-Like Illness (ILI) Surveillance from Sentinel Outpatient Providers ILI percent was above threshold at 3.9% in week 2.

ILI % ILI% Baseline Threshold (AZ) Number of Sites Reporting

9.0 60

8.0 50 7.0

6.0 40

5.0 30 4.0

% of Visits for ILI for Visits of % 3.0 20

2.0 Reporting Sites of Number 10 1.0

0.0 0

Week Ending Date

Percentage of Visits for ILI at Sentinel Providers, 2018–2019, Arizona 5% of Emergency Room visits are ILI in the past week compared to 8% for the same week in the 2017–2018 season.

18

16

14

12

10 % ILI % 8

6

4

2

0

Week 2% of hospitalizations (inpatient admissions) are ILI in the past week compared to 5% for the same week in the 2017–2018 season. 14

12

10

8 % ILI % 6

4

2

0

Week In Arizona, 4% of visits in the past week were ILI, compared to 3% nationally.

7

6

5

4 % ILI % 3

2

1

0

Week

Please see the new interactive influenza dashboard for more details on current and past seasons in Arizona. 2018-2019 Influenza Season

Visit azhealth.gov/flu to sign up for our weekly influenza reports! THANK YOU

Xandy Peterson | VPD Epi [email protected] | 480-202-0145

azhealth.gov @azdhs facebook.com/azdhs